Mutation Analysis (MutSig v2.0)
Stomach Adenocarcinoma (Primary solid tumor)
23 May 2013  |  analyses__2013_05_23
Maintainer Information
Citation Information
doi:10.7908/C10R9MGS
Maintained by Dan DiCara (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2013): Mutation Analysis (MutSig v2.0). Broad Institute of MIT and Harvard. doi:10.7908/C10R9MGS
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.

  • Working with individual set: STAD-TP

  • Number of patients in set: 221

Input

The input for this pipeline is a set of individuals with the following files associated for each:

  1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

  2. A .wig file that contains information about the coverage of the sample.

Summary

  • MAF used for this analysis:STAD-TP.final_analysis_set.maf

  • Significantly mutated genes (q ≤ 0.1): 42

  • Mutations seen in COSMIC: 499

  • Significantly mutated genes in COSMIC territory: 30

  • Genes with clustered mutations (≤ 3 aa apart): 886

  • Significantly mutated genesets: 18

  • Significantly mutated genesets: (excluding sig. mutated genes):0

Mutation Preprocessing

  • Read 221 MAFs of type "Broad"

  • Total number of mutations in input MAFs: 112521

  • After removing 38 mutations outside chr1-24: 112483

  • After removing 711 blacklisted mutations: 111772

  • After removing 1912 noncoding mutations: 109860

Mutation Filtering

  • Number of mutations before filtering: 109860

  • After removing 1339 mutations outside gene set: 108521

  • After removing 114 mutations outside category set: 108407

  • After removing 3 "impossible" mutations in

  • gene-patient-category bins of zero coverage: 106951

Results
Breakdown of Mutations by Type

Table 1.  Get Full Table Table representing breakdown of mutations by type.

type count
Frame_Shift_Del 2296
Frame_Shift_Ins 488
In_Frame_Del 202
In_Frame_Ins 9
Missense_Mutation 70652
Nonsense_Mutation 3548
Nonstop_Mutation 72
Silent 29387
Splice_Site 1555
Translation_Start_Site 198
Total 108407
Breakdown of Mutation Rates by Category Type

Table 2.  Get Full Table A breakdown of mutation rates per category discovered for this individual set.

category n N rate rate_per_mb relative_rate exp_ns_s_ratio
*CpG->T 25171 355853720 0.000071 71 5.8 2.1
*Np(A/C/T)->transit 22506 5121780072 4.4e-06 4.4 0.36 2
*ApG->G 3506 992607213 3.5e-06 3.5 0.29 2.1
transver 19662 6470241005 3e-06 3 0.25 5
indel+null 8066 6470241005 1.2e-06 1.2 0.1 NaN
double_null 107 6470241005 1.7e-08 0.017 0.0014 NaN
Total 79018 6470241005 0.000012 12 1 3.5
Target Coverage for Each Individual

The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).

Figure 1. 

Distribution of Mutation Counts, Coverage, and Mutation Rates Across Samples

Figure 2.  Patients counts and rates file used to generate this plot: STAD-TP.patients.counts_and_rates.txt

Needs description.

Figure 3.  Needs description.

Figure 4.  Needs description.

CoMut Plot

Figure 5.  Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

  • N = number of sequenced bases in this gene across the individual set

  • n = number of (nonsilent) mutations in this gene across the individual set

  • npat = number of patients (individuals) with at least one nonsilent mutation

  • nsite = number of unique sites having a non-silent mutation

  • nsil = number of silent mutations in this gene across the individual set

  • n1 = number of nonsilent mutations of type: *CpG->T

  • n2 = number of nonsilent mutations of type: *Np(A/C/T)->transit

  • n3 = number of nonsilent mutations of type: *ApG->G

  • n4 = number of nonsilent mutations of type: transver

  • n5 = number of nonsilent mutations of type: indel+null

  • n6 = number of nonsilent mutations of type: double_null

  • p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene

  • p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene

  • p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene

  • p_joint = p-value for clustering + conservation

  • p = p-value (overall)

  • q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 3.  Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 42. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank gene description N n npat nsite nsil n1 n2 n3 n4 n5 n6 p_classic p_ns_s p_cons p_joint p q
1 RHOA ras homolog gene family, member A 132155 14 13 10 0 1 5 0 8 0 0 9.3e-14 0.027 0.6 8.6e-06 0.000 0.000
2 PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 723978 62 48 31 2 10 40 3 8 1 0 6.1e-15 3.9e-07 0.02 0.00029 1.11e-16 6.70e-13
3 SMAD4 SMAD family member 4 374970 21 19 18 1 5 6 0 6 3 1 1.3e-13 0.024 0.19 0.000027 1.11e-16 6.70e-13
4 TP53 tumor protein p53 272497 103 99 66 1 28 21 2 14 37 1 2.2e-15 1.6e-11 0 0 <1.00e-15 <2.26e-12
5 CBWD1 COBW domain containing 1 210334 30 28 3 0 0 1 0 1 28 0 3e-15 0.007 0 0 <1.00e-15 <2.26e-12
6 KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 153529 25 25 6 0 0 20 0 5 0 0 4e-15 0.00027 0.00012 0 <1.00e-15 <2.26e-12
7 PGM5 phosphoglucomutase 5 305048 25 22 7 1 4 18 0 1 2 0 1e-10 0.00064 1 0 <1.00e-15 <2.26e-12
8 TRIM48 tripartite motif-containing 48 135763 14 14 2 1 0 13 0 1 0 0 2.6e-10 0.018 0.96 0 <1.00e-15 <2.26e-12
9 ARID1A AT rich interactive domain 1A (SWI-like) 1285806 45 41 45 2 6 5 1 4 27 2 4.6e-15 0.0007 0.46 0.66 1.03e-13 2.08e-10
10 IRF2 interferon regulatory factor 2 238325 17 15 16 2 5 2 0 5 4 1 1.8e-07 0.13 0.003 0.00078 3.25e-09 5.88e-06
11 SLITRK6 SLIT and NTRK-like family, member 6 558667 19 19 19 0 3 6 1 8 1 0 2.4e-09 0.0044 0.86 1 5.01e-08 8.24e-05
12 TUSC3 tumor suppressor candidate 3 237782 15 14 13 0 5 0 3 5 2 0 1.9e-08 0.026 0.58 0.37 1.39e-07 0.000198
13 CDH1 cadherin 1, type 1, E-cadherin (epithelial) 561265 19 18 18 5 1 6 1 7 4 0 0.0004 0.3 0.00069 0.000018 1.43e-07 0.000198
14 FBXW7 F-box and WD repeat domain containing 7 548512 20 19 13 1 11 4 0 0 5 0 2.6e-06 0.023 0.16 0.0031 1.53e-07 0.000198
15 PTH2 parathyroid hormone 2 47536 4 4 1 0 0 0 0 4 0 0 0.00095 0.32 0.11 0.000028 4.93e-07 0.000594
16 ZNF804B zinc finger protein 804B 895133 35 27 34 2 2 8 1 21 3 0 4.8e-08 0.0069 0.77 0.68 6.01e-07 0.000680
17 FAM46D family with sequence similarity 46, member D 255109 6 6 3 0 0 0 0 5 1 0 0.0089 0.46 0.11 0.000014 2.05e-06 0.00218
18 POTEG POTE ankyrin domain family, member G 261305 9 9 9 1 2 5 1 0 1 0 0.0018 0.11 0.73 0.00015 4.29e-06 0.00431
19 MAP2K7 mitogen-activated protein kinase kinase 7 219244 20 14 20 0 10 4 0 3 3 0 6e-07 0.00062 0.48 0.62 5.85e-06 0.00534
20 EDNRB endothelin receptor type B 303308 20 18 17 4 8 3 0 5 4 0 2.9e-06 0.19 0.88 0.13 5.91e-06 0.00534
21 B2M beta-2-microglobulin 82186 8 8 8 0 0 2 0 2 3 1 2.2e-06 0.14 0.15 0.24 8.06e-06 0.00694
22 TRIML2 tripartite motif family-like 2 263175 12 12 12 0 1 4 1 6 0 0 3.9e-06 0.029 0.1 0.17 1.01e-05 0.00832
23 HLA-B major histocompatibility complex, class I, B 217984 12 12 12 0 1 2 2 2 4 1 3.3e-06 0.03 0.059 0.27 1.33e-05 0.0105
24 IAPP islet amyloid polypeptide 61356 4 4 3 0 0 0 0 4 0 0 0.001 0.47 0.98 0.002 2.89e-05 0.0218
25 PTEN phosphatase and tensin homolog (mutated in multiple advanced cancers 1) 266766 18 14 16 4 1 4 0 6 7 0 0.000012 0.58 0.86 0.24 3.96e-05 0.0287
26 SPRYD5 SPRY domain containing 5 301898 13 12 10 1 0 0 2 5 6 0 7.4e-06 0.45 1 0.41 4.18e-05 0.0291
27 CNBD1 cyclic nucleotide binding domain containing 1 218431 9 9 7 1 0 1 3 5 0 0 0.000015 0.21 0.068 0.23 4.71e-05 0.0315
28 RPS6KA6 ribosomal protein S6 kinase, 90kDa, polypeptide 6 454067 15 13 13 0 3 1 1 5 5 0 8.5e-06 0.048 0.79 0.49 5.57e-05 0.0360
29 MXRA8 matrix-remodelling associated 8 171805 13 11 6 2 3 1 0 0 9 0 0.00011 0.45 0.68 0.04 5.90e-05 0.0368
30 CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 518587 21 20 19 3 8 2 0 10 1 0 0.000039 0.068 0.58 0.15 7.70e-05 0.0464
31 KCNMB2 potassium large conductance calcium-activated channel, subfamily M, beta member 2 159602 6 6 4 2 0 1 0 5 0 0 0.021 0.75 1 0.00033 8.88e-05 0.0518
32 OR4C16 olfactory receptor, family 4, subfamily C, member 16 205186 10 10 8 2 1 3 0 6 0 0 0.000076 0.42 0.86 0.095 9.33e-05 0.0527
33 WBSCR17 Williams-Beuren syndrome chromosome region 17 398022 22 20 20 4 9 6 3 3 1 0 0.000019 0.077 0.84 0.39 9.68e-05 0.0531
34 C17orf63 chromosome 17 open reading frame 63 12764 3 4 4 0 1 0 0 1 1 0 0.0001 0.32 NaN NaN 0.000101 0.0540
35 MAGEE2 melanoma antigen family E, 2 340871 7 7 5 0 1 1 0 2 3 0 0.012 0.32 0.84 0.00073 0.000108 0.0557
RHOA

Figure S1.  This figure depicts the distribution of mutations and mutation types across the RHOA significant gene.

PIK3CA

Figure S2.  This figure depicts the distribution of mutations and mutation types across the PIK3CA significant gene.

SMAD4

Figure S3.  This figure depicts the distribution of mutations and mutation types across the SMAD4 significant gene.

TP53

Figure S4.  This figure depicts the distribution of mutations and mutation types across the TP53 significant gene.

CBWD1

Figure S5.  This figure depicts the distribution of mutations and mutation types across the CBWD1 significant gene.

KRAS

Figure S6.  This figure depicts the distribution of mutations and mutation types across the KRAS significant gene.

PGM5

Figure S7.  This figure depicts the distribution of mutations and mutation types across the PGM5 significant gene.

TRIM48

Figure S8.  This figure depicts the distribution of mutations and mutation types across the TRIM48 significant gene.

ARID1A

Figure S9.  This figure depicts the distribution of mutations and mutation types across the ARID1A significant gene.

IRF2

Figure S10.  This figure depicts the distribution of mutations and mutation types across the IRF2 significant gene.

SLITRK6

Figure S11.  This figure depicts the distribution of mutations and mutation types across the SLITRK6 significant gene.

TUSC3

Figure S12.  This figure depicts the distribution of mutations and mutation types across the TUSC3 significant gene.

CDH1

Figure S13.  This figure depicts the distribution of mutations and mutation types across the CDH1 significant gene.

FBXW7

Figure S14.  This figure depicts the distribution of mutations and mutation types across the FBXW7 significant gene.

ZNF804B

Figure S15.  This figure depicts the distribution of mutations and mutation types across the ZNF804B significant gene.

FAM46D

Figure S16.  This figure depicts the distribution of mutations and mutation types across the FAM46D significant gene.

POTEG

Figure S17.  This figure depicts the distribution of mutations and mutation types across the POTEG significant gene.

MAP2K7

Figure S18.  This figure depicts the distribution of mutations and mutation types across the MAP2K7 significant gene.

EDNRB

Figure S19.  This figure depicts the distribution of mutations and mutation types across the EDNRB significant gene.

B2M

Figure S20.  This figure depicts the distribution of mutations and mutation types across the B2M significant gene.

TRIML2

Figure S21.  This figure depicts the distribution of mutations and mutation types across the TRIML2 significant gene.

HLA-B

Figure S22.  This figure depicts the distribution of mutations and mutation types across the HLA-B significant gene.

PTEN

Figure S23.  This figure depicts the distribution of mutations and mutation types across the PTEN significant gene.

SPRYD5

Figure S24.  This figure depicts the distribution of mutations and mutation types across the SPRYD5 significant gene.

CNBD1

Figure S25.  This figure depicts the distribution of mutations and mutation types across the CNBD1 significant gene.

RPS6KA6

Figure S26.  This figure depicts the distribution of mutations and mutation types across the RPS6KA6 significant gene.

MXRA8

Figure S27.  This figure depicts the distribution of mutations and mutation types across the MXRA8 significant gene.

CDH11

Figure S28.  This figure depicts the distribution of mutations and mutation types across the CDH11 significant gene.

KCNMB2

Figure S29.  This figure depicts the distribution of mutations and mutation types across the KCNMB2 significant gene.

OR4C16

Figure S30.  This figure depicts the distribution of mutations and mutation types across the OR4C16 significant gene.

WBSCR17

Figure S31.  This figure depicts the distribution of mutations and mutation types across the WBSCR17 significant gene.

C17orf63

Figure S32.  This figure depicts the distribution of mutations and mutation types across the C17orf63 significant gene.

COSMIC analyses

In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.

Table 4.  Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 30. Number of genes displayed: 10

rank gene description n cos n_cos N_cos cos_ev p q
1 ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 29 6 6 1326 6 0 0
2 KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 25 52 24 11492 166293 0 0
3 TP53 tumor protein p53 103 356 96 78676 26850 0 0
4 PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 62 220 54 48620 19016 0 0
5 FBXW7 F-box and WD repeat domain containing 7 20 91 13 20111 681 0 0
6 SMAD4 SMAD family member 4 21 159 17 35139 66 0 0
7 CDH1 cadherin 1, type 1, E-cadherin (epithelial) 19 185 11 40885 35 6.9e-12 4.5e-09
8 PTEN phosphatase and tensin homolog (mutated in multiple advanced cancers 1) 18 767 18 169507 551 1e-11 5.8e-09
9 APC adenomatous polyposis coli 35 839 18 185419 374 4.5e-11 2.2e-08
10 ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) 12 42 6 9282 75 2.7e-09 1.2e-06

Note:

n - number of (nonsilent) mutations in this gene across the individual set.

cos = number of unique mutated sites in this gene in COSMIC

n_cos = overlap between n and cos.

N_cos = number of individuals times cos.

cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.

p = p-value for seeing the observed amount of overlap in this gene)

q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Clustered Mutations

Table 5.  Get Full Table Genes with Clustered Mutations

num gene desc n mindist nmuts0 nmuts3 nmuts12 npairs0 npairs3 npairs12
2260 CBWD1 COBW domain containing 1 30 0 378 378 378 378 378 378
10164 PGM5 phosphoglucomutase 5 25 0 154 154 191 154 154 191
10268 PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 62 0 130 231 269 130 231 269
14157 TP53 tumor protein p53 103 0 114 252 521 114 252 521
7240 KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 25 0 85 175 177 85 175 177
14283 TRIM48 tripartite motif-containing 48 14 0 78 78 78 78 78 78
4892 FBXW7 F-box and WD repeat domain containing 7 20 0 22 24 24 22 24 24
8732 NBPF10 neuroblastoma breakpoint family, member 10 20 0 22 22 23 22 22 23
4426 ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 29 0 17 17 26 17 17 26
15089 XPOT exportin, tRNA (nuclear export receptor for tRNAs) 9 0 15 15 15 15 15 15

Note:

n - number of mutations in this gene in the individual set.

mindist - distance (in aa) between closest pair of mutations in this gene

npairs3 - how many pairs of mutations are within 3 aa of each other.

npairs12 - how many pairs of mutations are within 12 aa of each other.

Geneset Analyses

Table 6.  Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 18. Number of genesets displayed: 10

rank geneset description genes N_genes mut_tally N n npat nsite nsil n1 n2 n3 n4 n5 n6 p_ns_s p q
1 ARFPATHWAY Cyclin-dependent kinase inhibitor 2A is a tumor suppressor that induces G1 arrest and can activate the p53 pathway, leading to G2/M arrest. ABL1, CDKN2A, E2F1, MDM2, MYC, PIK3CA, PIK3R1, POLR1A, POLR1B, POLR1C, POLR1D, RAC1, RB1, TBX2, TP53, TWIST1 16 ABL1(4), CDKN2A(7), E2F1(2), MDM2(3), MYC(3), PIK3CA(62), PIK3R1(8), POLR1A(12), POLR1B(4), POLR1C(2), POLR1D(1), RB1(6), TBX2(3), TP53(103), TWIST1(1) 6653717 221 147 152 31 56 78 6 31 49 1 3.4e-09 <1.00e-15 <1.71e-13
2 PLK3PATHWAY Active Plk3 phosphorylates CDC25c, blocking the G2/M transition, and phosphorylates p53 to induce apoptosis. ATM, ATR, CDC25C, CHEK1, CHEK2, CNK, TP53, YWHAH 7 ATM(30), ATR(13), CDC25C(7), CHEK1(4), CHEK2(7), TP53(103), YWHAH(3) 5264371 167 129 129 15 45 34 5 32 48 3 5.9e-07 <1.00e-15 <1.71e-13
3 RBPATHWAY The ATM protein kinase recognizes DNA damage and blocks cell cycle progression by phosphorylating chk1 and p53, which normally inhibits Rb to allow G1/S transitions. ATM, CDC2, CDC25A, CDC25B, CDC25C, CDK2, CDK4, CHEK1, MYT1, RB1, TP53, WEE1, YWHAH 12 ATM(30), CDC25A(3), CDC25B(4), CDC25C(7), CDK2(3), CHEK1(4), MYT1(14), RB1(6), TP53(103), WEE1(2), YWHAH(3) 5794957 179 127 139 14 48 41 6 34 47 3 7e-10 <1.00e-15 <1.71e-13
4 PMLPATHWAY Ring-shaped PML nuclear bodies regulate transcription and are required co-activators in p53- and DAXX-mediated apoptosis. CREBBP, DAXX, HRAS, PAX3, PML, PRAM-1, RARA, RB1, SIRT1, SP100, TNF, TNFRSF1A, TNFRSF1B, TNFRSF6, TNFSF6, TP53, UBL1 13 CREBBP(27), DAXX(9), PAX3(7), PML(7), RARA(2), RB1(6), SIRT1(4), SP100(10), TNF(1), TNFRSF1A(3), TNFRSF1B(1), TP53(103) 6230239 180 122 142 25 57 43 4 28 47 1 1.5e-07 1.11e-15 1.71e-13
5 SA_G1_AND_S_PHASES Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 15 ARF1(4), CCND1(1), CDK2(3), CDKN1A(1), CDKN2A(7), CFL1(1), E2F1(2), E2F2(3), MDM2(3), NXT1(2), PRB1(2), TP53(103) 2761021 132 114 95 12 38 31 3 16 43 1 6.1e-08 1.67e-15 2.05e-13
6 RNAPATHWAY dsRNA-activated protein kinase phosphorylates elF2a, which generally inhibits translation, and activates NF-kB to provoke inflammation. CHUK, DNAJC3, EIF2S1, EIF2S2, MAP3K14, NFKB1, NFKBIA, PRKR, RELA, TP53 9 DNAJC3(3), EIF2S1(2), EIF2S2(3), MAP3K14(3), NFKB1(7), NFKBIA(1), RELA(3), TP53(103) 3207445 125 106 88 7 34 29 2 20 39 1 3.6e-09 3.77e-15 2.80e-13
7 CHEMICALPATHWAY DNA damage promotes Bid cleavage, which stimulates mitochondrial cytochrome c release and consequent caspase activation, resulting in apoptosis. ADPRT, AKT1, APAF1, ATM, BAD, BAX, BCL2, BCL2L1, BID, CASP3, CASP6, CASP7, CASP9, CYCS, EIF2S1, PRKCA, PRKCB1, PTK2, PXN, STAT1, TLN1, TP53 20 AKT1(3), APAF1(5), ATM(30), BAD(3), BAX(1), BCL2(2), BID(2), CASP3(2), CASP6(1), CASP7(2), CASP9(2), EIF2S1(2), PRKCA(3), PTK2(10), PXN(3), STAT1(7), TLN1(14), TP53(103) 8999666 195 131 156 21 57 46 11 30 48 3 1.2e-09 4.22e-15 2.80e-13
8 ATMPATHWAY The tumor-suppressing protein kinase ATM responds to radiation-induced DNA damage by blocking cell-cycle progression and activating DNA repair. ABL1, ATM, BRCA1, CDKN1A, CHEK1, CHEK2, GADD45A, JUN, MAPK8, MDM2, MRE11A, NBS1, NFKB1, NFKBIA, RAD50, RAD51, RBBP8, RELA, TP53, TP73 19 ABL1(4), ATM(30), BRCA1(14), CDKN1A(1), CHEK1(4), CHEK2(7), JUN(3), MAPK8(5), MDM2(3), MRE11A(2), NFKB1(7), NFKBIA(1), RAD50(9), RAD51(1), RBBP8(6), RELA(3), TP53(103), TP73(2) 9791154 205 137 167 22 51 47 8 44 52 3 7.8e-09 4.44e-15 2.80e-13
9 P53PATHWAY p53 induces cell cycle arrest or apoptosis under conditions of DNA damage. APAF1, ATM, BAX, BCL2, CCND1, CCNE1, CDK2, CDK4, CDKN1A, E2F1, GADD45A, MDM2, PCNA, RB1, TIMP3, TP53 16 APAF1(5), ATM(30), BAX(1), BCL2(2), CCND1(1), CCNE1(3), CDK2(3), CDKN1A(1), E2F1(2), MDM2(3), PCNA(2), RB1(6), TIMP3(3), TP53(103) 5961338 165 128 126 19 44 40 5 30 43 3 3.5e-07 4.66e-15 2.80e-13
10 P53HYPOXIAPATHWAY Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 19 ABCB1(18), AKT1(3), ATM(30), BAX(1), CDKN1A(1), CPB2(6), CSNK1A1(3), CSNK1D(2), FHL2(2), HIC1(5), HIF1A(5), HSPA1A(1), IGFBP3(5), MAPK8(5), MDM2(3), NFKBIB(5), NQO1(2), TP53(103) 6815341 200 134 162 20 56 47 6 33 55 3 1.2e-10 5.00e-15 2.80e-13

Table 7.  Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10

rank geneset description genes N_genes mut_tally N n npat nsite nsil n1 n2 n3 n4 n5 n6 p_ns_s p q
1 HSA00472_D_ARGININE_AND_D_ORNITHINE_METABOLISM Genes involved in D-arginine and D-ornithine metabolism DAO 1 DAO(8) 238419 8 8 8 0 3 1 1 1 2 0 0.086 0.002 1
2 SLRPPATHWAY Small leucine-rich proteoglycans (SLRPs) interact with and reorganize collagen fibers in the extracellular matrix. BGN, DCN, DSPG3, FMOD, KERA, LUM 5 BGN(1), DCN(5), FMOD(8), KERA(1), LUM(5) 1194047 20 19 20 4 10 4 1 5 0 0 0.13 0.31 1
3 EOSINOPHILSPATHWAY Recruitment of eosinophils in the inflammatory response observed in asthma occurs via the chemoattractant eotaxin binding to the CCR3 receptor. CCL11, CCL5, CCR3, CSF2, HLA-DRA, HLA-DRB1, IL3, IL5 8 CCL11(1), CCL5(1), CCR3(6), HLA-DRA(6), IL3(1) 999988 15 14 15 3 8 5 0 2 0 0 0.13 0.43 1
4 NUCLEOTIDE_SUGARS_METABOLISM GALE, GALT, TGDS, UGDH, UXS1 5 GALE(1), GALT(1), TGDS(3), UGDH(5), UXS1(3) 1268853 13 12 13 1 4 5 1 2 1 0 0.049 0.64 1
5 FOSBPATHWAY FOSB gene expression and drug abuse CDK5, FOSB, GRIA2, JUND, PPP1R1B 5 CDK5(2), FOSB(3), GRIA2(17), JUND(1), PPP1R1B(1) 1225092 24 20 24 5 6 9 1 6 2 0 0.13 0.66 1
6 HSA00031_INOSITOL_METABOLISM Genes involved in inositol metabolism ALDH6A1, TPI1 2 ALDH6A1(4), TPI1(1) 539342 5 5 5 1 2 2 1 0 0 0 0.36 0.73 1
7 PEPIPATHWAY Proepithelin (PEPI) induces epithelial cells to secrete IL-8, which promotes elastase secretion by neutrophils. ELA1, ELA2, ELA2A, ELA2B, ELA3B, GRN, IL8, SLPI 3 GRN(4), IL8(1), SLPI(1) 563163 6 5 6 2 3 2 0 1 0 0 0.5 0.77 1
8 HSA00643_STYRENE_DEGRADATION Genes involved in styrene degradation FAH, GSTZ1, HGD 3 FAH(3), GSTZ1(3), HGD(3) 730546 9 8 9 3 4 2 0 3 0 0 0.49 0.77 1
9 IL18PATHWAY Pro-inflammatory IL-18 is activated in macrophages by caspase-1 cleavage and, in conjunction with IL-12, stimulates Th1 cell differentiation. CASP1, IFNG, IL12A, IL12B, IL18, IL2 6 CASP1(2), IFNG(2), IL12A(2), IL12B(1), IL18(1) 980615 8 8 8 2 0 3 1 4 0 0 0.56 0.78 1
10 TCRMOLECULE T Cell Receptor and CD3 Complex CD3D, CD3E, CD3G, CD3Z, TRA@, TRB@ 3 CD3E(2) 375013 2 2 2 1 0 1 1 0 0 0 0.82 0.79 1
Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2013 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle